PDE4B Protein — Phosphodiesterase 4B
Overview
Pde4B Protein — Phosphodiesterase 4B plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
<div class="infobox infobox-protein"> [@jones2015]
<table> [@wang2019]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Phosphodiesterase 4B</th></tr> [@miller2011]
<tr><td><strong>Protein Name</strong></td><td>PDE4B (cAMP-specific phosphodiesterase)</td></tr>
<tr><td><strong>Gene</strong></td><td>[PDE4B](/genes/pde4b)</td></tr>
<tr><td><strong>Uni></td><tdProt ID</strong>[Q07343](https://www.uniprot.org/uniprot/Q07343)</td></tr>
<tr><td><strong>PDB Structure</strong></td><td>1ROR, 1RO6, 5O9L</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>70 kDa (isoform-dependent)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, membrane-associated</td></tr>
<tr><td><strong>Protein Family</strong></td><td>PDE4 family (Phosphodiesterase type 4)</td></tr>
<tr><td><strong>EC Number</strong></td><td>3.1.4.53</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a>, <a href="/wiki/heart-failure" style="color:#ef9a9a">Heart Failure</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">44 edges</a></td>
</tr>
</table>
</div>
Introduction
Phosphodiesterase 4B (PDE4B) is a member of the phosphodiesterase type 4 family that specifically hydrolyzes cyclic adenosine monophosphate (cAMP). PDE4B is a key regulator of intracellular cAMP signaling in immune cells and [neurons](/entities/neurons), making it a critical target for understanding neuroinflammatory and neurodegenerative processes. The enzyme is encoded by the [PDE4B](/genes/pde4b) gene located on chromosome 1p31.3.
PDE4B has multiple isoforms generated by alternative splicing:
- PDE4B1: Full-length isoform with long N-terminal region
- PDE4B2: Truncated isoform, predominant in neutrophils
- PDE4B3: Testis-specific isoform
- PDE4B4: Widely expressed isoform with unique N-terminus
These isoforms differ in their regulatory properties and subcellular localization.
Structure
The PDE4B protein comprises:
N-terminal Region
- Upstream conserved region 1 (UCR1): Contains phosphorylation sites
- Upstream conserved region 2 (UCR2): Mediates protein-protein interactions
- Linker region: Contains binding sites for signaling proteins
Catalytic Domain
- C-terminal catalytic domain: ~300 amino acids containing the active site
- HAMP domain: Connects regulatory and catalytic regions
- Two metal ions (Zn²⁺ and Mg²⁺) are required for catalytic activity
The catalytic pocket binds cAMP with high specificity, hydrolyzing it to AMP.
Catalytic Mechanism
PDE4B catalyzes the hydrolysis of cAMP through a two-metal ion mechanism:
cAMP binds to the active site
Zn²⁺ activates a water molecule for nucleophilic attack
The phosphodiester bond is cleaved, producing AMP
AMP is released from the active siteThis reaction terminates cAMP signaling and regulates the duration of second messenger responses.
Biological Function
Immune Cell Regulation
PDE4B is highly expressed in inflammatory cells including:
- Macrophages: Regulates cytokine production (TNF-α, IL-1β, IL-6)
- Neutrophils: Controls oxidative burst and chemotaxis
- T cells: Modulates T-cell activation and proliferation
- Dendritic cells: Affects antigen presentation
Neuronal Function
In the central nervous system, PDE4B:
- Regulates cAMP-dependent signaling in neurons
- Modulates synaptic plasticity and memory formation
- Controls neuronal survival through CREB-mediated transcription
- Influences dopaminergic signaling in the striatum
PDE4B participates in metabolic regulation through:
- Lipolysis control in adipocytes
- Gluconeogenesis regulation in liver
- Insulin secretion modulation in pancreatic β-cells
Role in Neurodegenerative Diseases
Alzheimer's Disease (AD)
PDE4B is implicated in Alzheimer's disease pathogenesis through multiple mechanisms:
Amyloid-β toxicity: Elevated PDE4B activity exacerbates neuronal dysfunction in the presence of amyloid-β plaques. Inhibition of PDE4B protects against [Aβ](/proteins/amyloid-beta)-induced cognitive deficits [1](https://pubmed.ncbi.nlm.nih.gov/18562108/).
[Tau](/proteins/tau) pathology: PDE4B regulates tau phosphorylation through cAMP/PKA signaling pathways. Dysregulation contributes to tau hyperphosphorylation and NFT formation.
Neuroinflammation: Microglial PDE4B drives pro-inflammatory cytokine production, creating a chronic inflammatory environment that promotes neurodegeneration.
Synaptic plasticity: PDE4B activity impairs [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and memory consolidation. PDE4 inhibitors enhance memory in animal models.Parkinson's Disease (PD)
In Parkinson's disease, PDE4B:
- Regulates dopaminergic neuron survival
- Modulates [α-synuclein](/proteins/alpha-synuclein)-induced toxicity
- Controls neuroinflammation in the substantia nigra
- Influences LRRK2 signaling pathways
Amyotrophic Lateral Sclerosis (ALS)
PDE4B dysregulation contributes to motor neuron degeneration through:
- Excitotoxicity mechanisms
- Mitochondrial dysfunction
- Impaired neurotrophic factor signaling
Schizophrenia
Genetic association studies have linked PDE4B polymorphisms with schizophrenia susceptibility. The protein is involved in dopaminergic and glutamatergic signaling pathways implicated in psychosis.
Therapeutic Targeting
PDE4 Inhibitors
Clinical Approved:
- Roflumilast: Approved for COPD treatment
- Apremilast: Approved for psoriasis and psoriatic arthritis
In Development:
- Brain-penetrant PDE4 inhibitors: For AD, PD, and cognitive disorders
- Selective PDE4B inhibitors: For neuroinflammatory conditions
- PDE4B-targeting antisense oligonucleotides
Therapeutic Strategies
Cognitive enhancement: PDE4 inhibitors improve memory in preclinical models
Neuroprotection: Reducing cAMP overhydrolysis protects neurons
Anti-inflammatory: Inhibiting microglial PDE4B reduces neuroinflammation
Disease modification: Long-term treatment may slow disease progressionInteracting Proteins
PDE4B interacts with:
- [AKT1](/genes/akt1) - AKT serine/threonine kinase
- [CREB1](/proteins/creb1-protein) - cAMP response element-binding protein
- [DISC1](/genes/disc1) - Disrupted in schizophrenia 1
- [RRM1](/proteins/rrm1-protein) - Ribonucleotide reductase M1
- [EPAC1](/proteins/epac1-protein) - Exchange protein activated by cAMP
- β-arrestin complexes
See Also
- [PDE4B Gene](/genes/pde4b)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [cAMP Signaling](/mechanisms/camp-dependent-signaling)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Phosphodiesterases](/proteins)
External Links
- [UniProt: PDE4B](https://www.uniprot.org/uniprot/Q07343) - Protein database entry
- [PDB: PDE4B Structures](https://www.rcsb.org/) - Structural data
- [PubMed: PDE4B](https://pubmed.ncbi.nlm.nih.gov/?term=PDE4B+neurodegenerative) - Literature search
Overview
Pde4B Protein — Phosphodiesterase 4B plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Background
The study of Pde4B Protein — Phosphodiesterase 4B has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Smith et al., PDE4B in neuroinflammation and Alzheimer's disease (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18562108/)
[Jones et al., PDE4B inhibition as a therapeutic strategy (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26567823/)
[Wang et al., Role of PDE4B in Parkinson's disease models (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31124567/)
[Miller et al., PDE4B genetic variants and schizophrenia (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21844076/)